Pre-made Basiliximab benchmark antibody ( Whole mAb, anti-IL2RA therapeutic antibody, Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Basiliximab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-049-1mg	1mg	3090
GMP-Bios-ab-049-10mg	10mg	Inquiry
GMP-Bios-ab-049-100mg	100mg	Inquiry
GMP-Bios-ab-049-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Basiliximab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody
INN Name	Basiliximab
Target	IL2RA
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	1mim:HL/3iu3:AB:CD:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	1996
Year Recommended	1997
Companies	Cerimon Pharmaceuticals;Novartis
Conditions Approved	Renal transplant rejection;Transplant rejection
Conditions Active	na
Conditions Discontinued	Ulcerative colitis;Uveitis
Development Tech	na